Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

Chemotherapy or Chemotherapy Plus PD-1 Antibody in HER 2 Insertion or Amplification Advanced Non-small Cell Lung Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04324125

Enrollment

Registered

2020-03-27

Start date

2020-03-24

Completion date

2025-03-24

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Brief summary

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.

Detailed description

Main enrolled criteria: Her2 insertion advanced NSCLC Her 2 amplification advanced NSCLC Failed with standard chemotherapy No history of PD-1/ PD-L1 antibody using

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * HER 2 Insertion or Amplification * First Diagnosis and Treatment * Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody

Exclusion criteria

* Patients received antitumor treatment before * Patients with contraindication of chemotherapy * Pregnant or breast feeding women

Design outcomes

Primary

Measure	Time frame	Description
PFS	may 2020- may 2021 (1 year)	Progression free survival

Secondary

Measure	Time frame	Description
OS	may 2020- may 2021 (1 year)	Overall survival
ORR	may 2020- may 2021 (1 year)	To measure the patients's overall response rate

Countries

China

Contacts

Primary ContactYongchang Zhang, MD

zhangyongchang@csu.edu.cn+8613873123436

Backup ContactNong Yang, MD

yangnong0217@163.com+8613055193557

Outcome results